Test investigation
Adalimumab level and Ab
Laboratory offering test
Referral laboratory
Units
AU/mL
Also known as/Frequency of test
Humira; Exemptia
Indications
Diseases such as ulcerative colitis and Crohn’s disease respond to anti-Tumour Necrosis Factor alpha (TNF-α) therapy (e.g. Adalimumab/ infliximab). During treatment some patients can generate high levels of anti-drug antibodies (ADAs) which negate therapeutic effect. The serum concentration of the drug immediately prior to re-infusion (trough level) is needed to interpret the relevance of ADAs. Please refer to specialist guidelines for monitoring
Comments precautions
Plasma NOT acceptable. Referred outside of EPA
Sample type
Serum
Turnaround times (TAT) Urgent/Routine/GP or OPD
2 weeks
Reference intervals
<5 AU/mL Therapeutic values for Adalimumab (or biosimilar) vary according to pathology